Hepatology Information Center Archive
Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
End-of-treatment HBsAg levels may be a clinically useful biomarker to predict HBV relapse in patients with chronic hepatitis B regardless of HBeAg status.
Increased adiposity in childhood may negatively impact liver function in children as young as 8 years old.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
BMI is positively correlated with increased hepatocellular carcinoma in patients with chronic HBV, though the risk is greater in women.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.
TDF did not reduce mother-to-child HBV transmission in mothers taking hepatitis B Ig and HBV vaccine.
Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.
Technical variant grafts may be better than whole grafts for living donor liver transplants in children.
The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.
Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.
Primary gastrinomas of the hepatobiliary tract may occur in patients with Zollinger-Ellison syndrome
Lymph nodes proximal to hepatic or biliary gastrinomas will likely require extraction as many in the surround region will have metastasized.
Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.
The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
A 38-year old nonalcoholic patient consumed Epsom salt in large quantities for a short period of time and developed jaundice and steatohepatitis.
Mislabeling of herbal and dietary supplements is common, occurring in more than half of products tested.
Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America have added updates to the hepatitis C guidelines to include kidney transplant, pregnant, and pediatric patients.
The FDA has approved Opdivo (nivolumab) injection for the treatment of patients with HCC who have been previously treated with sorafenib.
The 3-part plan to halt the outbreak of hepatitis A focuses on immunization, sanitation and education with most of the efforts focused on the homeless population who are the most at-risk population.
The results show no evidence to support a hypothesis of differential impact of interferon and direct-acting antiviral-based cure on risk for HCC occurrence and recurrence.
Patients with childhood-onset IBD have an increased risk of cancer, especially gastrointestinal cancers, lymphoid neoplasms, and skin cancer,
No significant association was observed between coffee consumption and risk of biliary tract cancer, but there was evidence of an inverse correlation between coffee consumption and liver cancer risk.
A Mediterranean diet with antioxidant supplementation contributes to improving lipid profile and insulin sensitivity parameters in patients with non-alcoholic fatty liver disease.
The increase in the demand for liver transplantation for nonalcoholic steatohepatitis is expected to continue with the current population obesity trends.
The American Academy of Pediatrics recommends that the first dose of the hepatitis B vaccine should be given within the first 24 hours of life.
Primary care providers and nurse practitioners achieve the same sustained virologic response rates as specialists.
The AAFP has created an alcohol screening practice manual to help family physicians prevent alcohol misuse.
The use of palliative care increased from 2006 to 2012 among patients with end-stage liver disease.
The prompt increased hepatitis C screening rates among baby boomers in primary care by 5-fold.
Telbivudine administered during early and middle pregnancy prevented hepatitis B transmission from mother to infants in all participants receiving antiviral treatment.
HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.
The update includes 30 new medicines for adults and 25 for children and groups antibiotics into 3 distinct categories.
The score could help predict advanced colorectal neoplasia in adults younger than 50 years of age.
The Rotterdam Study found that frequent coffee and herbal tea consumption is associated with lower liver stiffness in the general population.
Hepatitis C treatment in HIV coinfection cases is effective with standardized nurse and pharmacist support for patients in an urban clinic.
The universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents.
Researchers conducted a meta-analysis to determine the association between coffee consumption and risk of hepatocellular carcinoma.
Pregnant women with a high hepatitis B viral load who receive tenofovir have a reduced risk for passing the virus to their child.
The guideline is intended to be an educational device to provide information that may assist endoscopists in providing care to patients.
The researchers found that the average survival after surgery for those receiving capecitabine was longer compared with those who only had surgery.
Gluten-rich food may lead to symptom onset, specifically early satiety, in patients with functional dyspepsia.
The guidelines facilitate a holistic, lifelong approach to the management of patients with primary biliary cholangitis.
The updated guidelines include substantial changes in the management of hepatitis B based on the latest scientific evidence.
Treatment was effective in patients under 6 years who received 50 mg/day of zinc as an initial dose.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of HCV.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.
Patients with chronic HCV infection who have achieved a sustained virologic response with treatment may still be at risk for complications such as hepatocellular carcinoma.
The guideline will help clinicians determine the appropriate treatment of patients with metastatic pancreatic cancer.
Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.
Harvoni and Sovaldi have been approved for pediatric patients with HCV genotypes.
Regimens for the treatment of hepatitis C that included ribavirin had more mild or moderate adverse events than those without.
Drug-drug interactions are common in patients taking hepatitis C virus medications, and consulting with a pharmacist can be beneficial.
A high BMI is associated with an increased risk for severe liver disease, and the risk is higher in those who also have type 2 diabetes mellitus.
Implementation of the FODMAP diet is an effective strategy to manage symptoms of IBS, including bloating and abdominal pain.
Thirty-eight of 231 NCGS patients showed gluten-specific symptoms when completing the placebo-controlled gluten challenge.
The American College of Gastroenterology has released recommendations of preferred approaches for diagnosing and evaluating patients with abnormal liver test results.
Surgical intervention after 24.5 days of acute pancreatitis may be beneficial for reducing postoperative complications.
Investigators have proposed an algorithm to facilitate the decision-making process of clinical care for patients with very early hepatocellular carcinoma.
HCV infection is associated with cancers such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.
Serum uric acid concentrations and fructose consumption are associated with non-alcoholic steatohepatitis in children with non-alcoholic fatty liver disease.
The procedure could be used as alternative to bariatric surgery for selected patients with obesity.
Diabetes could increase the risk of developing hepatocellular carcinoma in patients with hepatitis C.
A VA center in Wisconsin is advising veterans to be screened for hepatitis and HIV after receiving care from a dentist who did not follow VA procedures.
Researchers described a new method to quantify hepatic fibrogenesis flux rates in the liver tissue and noninvasively in blood.
Treatment for 12 or 24 weeks is safe and efficacious for kidney transplant recipients with hepatitis C virus.
Researchers identified an interaction between ribavirin with paritaprevir/ritonavir/ombitasvir and dasabuvir.
The cost of the new hepatitis C drugs in low- and certain middle-income countries is rapidly declining, according to a WHO study.
A 50-year-old man presents to the emergency department with abdominal pain, nausea, jaundice, and dark urine.
Timely administration of antibiotics was associated with a 30% reduction in 30 day mortality.
Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.
The ultimate goal should be to more closely regulate potentially injurious ingredients in herbal and dietary supplements.
The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
Total alcohol abstinence is the cornerstone of treatment for patients with alcohol use disorders and alcoholic liver disease.
Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.
Physical Activity reduces intrahepatic lipid content and markers of hepatocellular injury in patients with NAFLD and this effect correlated with baseline body mass index.
In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.
The mortality rate from pancreatic cancer is significantly higher in the American region than in the European and Western Pacific regions.
HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.
In patients with primary biliary cholangitis obeticholic acid was associated with significant decreases in alkaline phosphatase and total bilirubin levels.
A new hepatology rotation increased the mean comfort level for managing several liver diseases.
Researchers found significant differences on MRI between malignant and benign hypovascular lesions of the liver.
Most cases of chronic pancreatitis in women are from nonalcoholic etiologies, according to researchers.
In a study, 24% of confiscated drug snorting straws tested positive for human blood.
Patients previously treated for HCC have a high risk of tumor recurrence in the long term.
At 12 months, 21.2% of patients had developed de novo gallbladder disease.
Patients with HIV infection and elevated viral load are likely to progress to advanced hepatic fibrosis.
The combination drug treats 6 strains of chronic hepatitis C.
Older teen adolescents who are overweight are at an increased risk of developing liver cirrhosis later in life.
A clinical practice guideline offers recommendations on the best course of treatment for patients with potentially treatable pancreatic cancer.
Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.
Median overall survival was 11.9 months in patients receiving gemcitabine plus erlotinib.
The FDA has approved Ocaliva to treat patients with primary biliary cholangitis who have not responded or are intolerant to ursodeoxycholic acid.
Patients who underwent orthotopic liver transplants were less likely to be readmitted to the hospital when treated via a specialized protocol.
The number of deaths associated with hepatitis C is higher than the total number of deaths resulting from 60 other infectious diseases.
Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma